Abstract
Coronary heart disease, traditionally considered a problem predominantly for men, is currently the leading cause of mortality in adult women in the United States, responsible for about 250,000 deaths annually. The substantial age dependency of coronary heart disease in women is important in that one of eight or nine women aged 45 to 64 years has clinical manifestations of coronary heart disease, in contrast to one of three women older than 65 years. Despite these data, until very recently, most information used to guide preventive strategies, clinical recognition, and therapy of coronary heart disease in women was extrapolated from studies conducted predominantly or exclusively in middle-aged men.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Suggested Reading
Agency for Healthcare Research and Quality. Results of systematic review of research on diagnosis and treatment of coronary heart disease in women. Evidence Report/Technology Assessment Number 80. U.S. Department of Health and Human Services, Public Health Services. AHRQ Pub. No. 03-E034, May 2003.
Agency for Healthcare Research and Quality. Diagnosis and treatment of coronary heart disease in women: Systematic reviews of evidence on selected topics. Evidence Report/Technology Assessment Number 81. U.S. Department of Health and Human Services, Public Health Services. AHRQ Pub. No. 03-E036, May 2003.
American Diabetes Association. Implication of the Diabetes Control and Complications Trial. Diabetes Care 2003;26:S25.
American Heart Association. Heart Disease and Stroke Statistics—2003 Update. Dallas, TX: American Heart Association; 2002.
Chobanian A, Bakris G, Black H, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003;289:2560–72.
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97.
Grady D, Herrington D, Bittner V, et al. for the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49–57.
Mosca L, Appel LJ, Benjamin EJ, et al. Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women. Expert Panel/Writing Group, American Heart Association. Circulation 2004;109(5):672–93.
Wenger NK, guest ed. Symposium: gender differences in cardiac imaging. Am J Card Imag 1996;10:42–88.
Wenger NK. Coronary heart disease: the female heart is vulnerable. Prog Cardiovasc Dis 2003;46:199–229.
Wenger NK. Menopausal hormone therapy. Is there evidence for cardiac protection? In Contemporary Cardiology: Coronary Disease in Women: Evidence-Based Diagnosis and Treatment. LJ Shaw, RF Redberg (eds). Totowa, NJ: Humana Press Inc.; 2003: pp 321–48.
Writing Group for the Women’s Health Initiative Investigators. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women. Principal results from the Women’s Health Initiative Randomized Controlled Trial. JAMA 2002;288:321–33.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Wenger, N.K. (2007). Coronary Heart Disease in Women: Diagnosis, Evaluation, and Preventive Therapy. In: Primary Care in Obstetrics and Gynecology. Springer, New York, NY. https://doi.org/10.1007/978-0-387-32328-2_13
Download citation
DOI: https://doi.org/10.1007/978-0-387-32328-2_13
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-32327-5
Online ISBN: 978-0-387-32328-2
eBook Packages: MedicineMedicine (R0)